Dairy Peptides and Blood Pressure: The Full Evidence

Food Bioactive Peptides

89% ACE inhibition from optimized whey hydrolysate

A 2025 study used deep learning to optimize enzymatic hydrolysis of whey protein, achieving 89% ACE inhibition at 1 mg/mL concentration, higher than any single-enzyme approach.

Jiang et al., Journal of Agricultural and Food Chemistry, 2025

Jiang et al., Journal of Agricultural and Food Chemistry, 2025

View as image

Milk contains roughly 3.3% protein by weight. Most of that protein is casein (80%) and whey (20%). Both are precursors of bioactive peptides that are invisible until the protein is broken apart by enzymes, fermentation, or digestion. Among the most studied bioactive peptides in food science are those that inhibit angiotensin-converting enzyme (ACE), the same enzyme targeted by pharmaceutical ACE inhibitors like lisinopril and enalapril. The evidence that dairy derived peptides lower blood pressure is extensive but complicated: dozens of in vitro studies show potent ACE inhibition, animal studies confirm the effect, and some human trials show modest blood pressure reductions, while others show nothing.

For a broader view of bioactive peptides across the food supply, dairy is the most researched but not the only source. The pillar article on egg-derived bioactive peptides covers another major protein source with overlapping mechanisms.

How Milk Proteins Become ACE Inhibitors

ACE (angiotensin-converting enzyme) converts angiotensin I to angiotensin II, a potent vasoconstrictor that raises blood pressure. Pharmaceutical ACE inhibitors block this conversion. Dairy-derived peptides do the same thing, but with lower potency and through a food matrix rather than a pharmaceutical one.

The peptides do not exist in intact milk. They are encrypted within the primary sequence of casein and whey proteins, released only when the protein is cleaved. Three pathways produce them:

Enzymatic hydrolysis. Proteases (pepsin, trypsin, chymotrypsin, or commercial enzymes like alcalase and thermolysin) cut milk proteins at specific sites, liberating short peptide fragments. The enzyme choice determines which peptides are released. Jiang et al. (2025) used deep learning to identify an optimal multienzyme combination that achieved 89% ACE inhibition from whey protein hydrolysate, with the optimized blend outperforming any single enzyme. The resulting peptides maintained over 80% ACE inhibition after simulated gastrointestinal digestion, suggesting they survive the stomach and reach the intestine intact.^[1]

Fermentation. Lactic acid bacteria during yogurt, cheese, or kefir production secrete proteases that partially digest milk proteins. Pipaliya et al. (2025) showed that sheep milk fermented with Lacticaseibacillus paracasei for 48 hours at 37 degrees Celsius produced peptides with combined ACE-inhibitory, antidiabetic, and anti-inflammatory activity. The ACE-inhibitory potency increased with fermentation duration, plateauing at 48 hours.^[2]

Gastrointestinal digestion. Your own digestive enzymes liberate bioactive peptides from milk proteins during normal digestion. Ignot-Gutierrez et al. (2026) tracked peptide release from whey protein concentrate during simulated digestion and found that the digestion products stimulated CCK (cholecystokinin) secretion in enteroendocrine cells, demonstrating that the bioactive peptides are functionally active as produced by the digestive system itself.^[3]

Casein vs Whey: Different Peptide Profiles

Casein and whey proteins produce different peptide profiles when hydrolyzed. Iwaniak et al. (2025) systematically compared three bovine milk protein preparations: micellar casein concentrate (MCC), serum protein concentrate (SPC, predominantly whey), and a casein-buttermilk blend (MBP). Using both in silico prediction and in vitro validation, they found casein-derived preparations produced a larger number of ACE-inhibitory peptides, while whey-derived peptides showed higher DPP-IV inhibitory activity. Both sources also yielded antioxidant peptides, though with different profiles.^[4]

The review by Saito (2008) catalogued the primary ACE-inhibitory peptides from each source. From casein: VPP (Val-Pro-Pro) and IPP (Ile-Pro-Pro) are the most studied, along with longer sequences like FFVAPFPEVFGK. From whey: alpha-lactalbumin and beta-lactoglobulin yield distinct ACE-inhibitory fragments. The proline-rich C-terminal of many dairy peptides is critical for ACE binding, as proline fits into the enzyme's active site pocket.^[5]

Zhang et al. (2025) extended this work to goat milk, identifying unique ACE-inhibitory peptides not found in bovine sources. Using peptidomics and molecular docking, they showed that goat casein hydrolysates contain peptides that bind ACE at the same catalytic zinc site as pharmaceutical inhibitors, but with lower binding energy. The goat-derived peptides also showed antioxidant activity through separate mechanisms.^[6]

For more on how casein and whey peptides function beyond blood pressure, including their effects on satiety, immune modulation, and antimicrobial activity, the evidence landscape is broad.

The Human Clinical Evidence

The 2025 Casein Peptide RCT

Li et al. (2025) conducted a double-blind, randomized, placebo-controlled trial in prehypertensive and hypertensive patients using a hydrolyzed casein peptide tablet containing two specific peptides: GPFPIIV and FFVAPFPEVFGK (designated HCP-C7C12). After 12 weeks, the casein peptide group showed a systolic blood pressure reduction of 10.3 mmHg compared to placebo. The study also found that the casein peptide reshaped gut microbiota composition, with changes in specific bacterial genera correlating with blood pressure reduction. This microbiome effect suggests a mechanism beyond direct ACE inhibition.^[7]

The 10.3 mmHg effect is larger than what earlier lactotripeptide trials typically showed (1.7-4.0 mmHg pooled). Several factors may explain the difference. The peptide sequences used (GPFPIIV and FFVAPFPEVFGK) are different from the VPP and IPP lactotripeptides tested in most earlier studies, and the longer peptide (FFVAPFPEVFGK, a 12-residue sequence) may interact with ACE differently than the tripeptides. The dose and formulation as a tablet, rather than a fermented milk drink, may also affect bioavailability. The study population and sample size matter: this was a single trial and requires replication before the 10.3 mmHg figure can be considered reliable.

The gut microbiome finding is the most novel aspect of this trial. The casein peptide group showed shifts in specific bacterial genera that are associated with short-chain fatty acid production, including increased Bifidobacterium and Lactobacillus abundance. Short-chain fatty acids, particularly propionate and butyrate, have established effects on blood vessel relaxation through G-protein-coupled receptors (GPR41 and GPR43) on vascular smooth muscle. If casein peptides act partly by feeding beneficial gut bacteria rather than (or in addition to) directly inhibiting ACE, it would explain why the effect took weeks to develop, why it varied across populations with different baseline microbiomes, and why in vitro ACE inhibition potency has been a poor predictor of clinical efficacy.

Earlier Lactotripeptide Meta-Analyses

The VPP and IPP lactotripeptides have been tested in over 20 randomized trials. Meta-analyses of these studies show:

• Pooled systolic blood pressure reductions of 1.7-4.0 mmHg
• Larger effects in Asian populations than in European populations
• Dose-dependent responses, with higher IPP/VPP doses producing greater reductions
• Effects primarily in mildly hypertensive subjects, with minimal effects in normotensive individuals

The foundation of the data is that the effect is real but small. A 3 mmHg systolic reduction across a population would reduce cardiovascular events at the epidemiological level. Large observational studies estimate that every 2 mmHg population-wide reduction in systolic blood pressure reduces stroke mortality by about 10% and ischemic heart disease mortality by about 7%. But for an individual patient, a 3 mmHg change is difficult to distinguish from day-to-day measurement variability. Two notable negative trials in untreated European populations found no blood pressure effect at all, raising questions about population-specific responses.

The ethnic variability is one of the most puzzling features of the data. Japanese and Finnish populations have consistently shown the strongest responses to lactotripeptides. Trials in Dutch, British, and Danish populations have generally been negative. Whether this reflects genetic differences in ACE polymorphisms, baseline dietary habits, gut microbiome composition, or study design differences remains unresolved. The inconsistency has prevented regulatory approval of blood pressure claims for dairy peptide products in Europe, while Japan has approved several fermented milk products with specific health claims for blood pressure.

Bioavailability Challenges

Whether these peptides survive digestion in sufficient quantities to inhibit ACE systemically remains debated. The IC50 values (concentration needed for 50% ACE inhibition) for most dairy peptides are in the micromolar range, orders of magnitude higher than pharmaceutical ACE inhibitors like captopril or lisinopril, which operate in the nanomolar range. This means dairy peptides must achieve plasma concentrations roughly 1,000 times higher than pharmaceutical ACE inhibitors to produce the same degree of enzyme blockade. Whether oral consumption of fermented milk or peptide supplements achieves these concentrations is uncertain.

Several pharmacokinetic studies have detected VPP and IPP in human plasma after oral consumption, but at low concentrations and with rapid clearance. The peptides appear in blood within 30-60 minutes and are largely cleared within 4-6 hours, suggesting that any ACE-inhibitory effect would be transient. This short duration of action contrasts with the sustained effects reported in some clinical trials (measured over weeks), further supporting the hypothesis that mechanisms beyond direct ACE inhibition are involved.

Chopada et al. (2023) purified novel antihypertensive and antioxidative peptides from whey protein fermented with Lactobacillus plantarum, demonstrating in vitro ACE inhibition and validating molecular mechanisms through computational docking. However, the gap between in vitro potency and in vivo efficacy remains a persistent challenge for the field.^[8]

Beyond ACE: Multiple Mechanisms

The assumption that dairy peptides lower blood pressure solely through ACE inhibition is likely incomplete. The Li et al. trial's finding that casein peptides reshape gut microbiota suggests an indirect mechanism: altered microbial metabolite production (short-chain fatty acids, for example) can influence vascular tone and inflammation through pathways independent of ACE.

Kapoor et al. (2025) reviewed the full range of bioactive milk peptide mechanisms, including opioid-like activity (casomorphins), immunomodulation, mineral binding (caseinophosphopeptides that enhance calcium absorption), and antimicrobial effects. The blood pressure-lowering activity of dairy peptides may involve a combination of direct ACE inhibition, antioxidant protection of the vascular endothelium, and microbiome-mediated effects on systemic inflammation.^[9]

Shukla et al. (2022) reviewed the broader landscape of food-derived antihypertensive peptides, noting that dairy remains the most extensively studied source but that comparable ACE-inhibitory peptides have been identified in soy, fish, egg, and cereal proteins. The mechanism appears conserved across sources: short, proline-rich peptides fit the ACE active site regardless of the parent protein.^[10]

The practical implication of multiple mechanisms is that ACE inhibition assays, while useful for screening, may not predict clinical efficacy. A peptide with moderate ACE-inhibitory activity in vitro might produce substantial blood pressure effects in vivo if it also modulates the gut microbiome, acts as an antioxidant, or influences other vasoactive pathways. Conversely, a potent ACE inhibitor in the test tube might have no clinical effect if it is degraded before reaching the circulation. This disconnect between in vitro potency and clinical efficacy has been the central frustration of the field for two decades.

Industrial Applications and Waste Valorization

Damen et al. (2026) demonstrated that dairy white wastewater, a byproduct of industrial cleaning processes that is normally discarded, contains residual milk proteins that can be hydrolyzed into antihypertensive, antidiabetic, and antioxidant peptides. Using four different enzymes (pepsin, trypsin, thermolysin, and pronase E), they found the wastewater hydrolysates produced ACE-inhibitory and DPP-IV-inhibitory peptides comparable to those from pure milk protein.^[11]

This finding has practical implications. The dairy industry generates enormous volumes of wastewater, and converting it into a source of bioactive peptides would add value to what is currently a disposal cost. The peptides identified in wastewater hydrolysates are the same sequences found in conventional milk hydrolysates, confirming that the protein composition of the wastewater is sufficient for bioactive peptide production.

The convergence of AI-driven enzyme optimization, waste stream valorization, and microbiome research is reshaping the field. Traditional dairy peptide research focused narrowly on ACE inhibition and blood pressure. The current trajectory is toward multifunctional peptide products: hydrolysates that simultaneously provide ACE-inhibitory, DPP-IV-inhibitory (relevant to blood sugar regulation), antioxidant, and prebiotic effects. Whether these multifunctional profiles translate into measurable health outcomes in humans remains to be tested, but the reductive approach of studying single peptides against single targets has yielded diminishing returns. The Li et al. RCT, which found microbiome changes alongside blood pressure reduction, points toward a more integrative model of how food-derived peptides influence health.

Fermented food peptides from kimchi, kefir, and similar products represent another route to the same endpoint: microbial proteases during fermentation release ACE-inhibitory peptides from whatever protein substrate is present. Similarly, fish-derived collagen peptides contain distinct ACE-inhibitory sequences from marine protein sources, broadening the landscape of food-derived antihypertensives beyond terrestrial dairy.

The Bottom Line

Dairy proteins are the most extensively studied source of food-derived ACE-inhibitory peptides. Both casein and whey yield distinct antihypertensive peptide profiles through enzymatic hydrolysis, fermentation, or normal digestion. A 2025 human RCT showed a 10.3 mmHg systolic reduction with specific casein peptides, though earlier meta-analyses of lactotripeptide trials suggest more modest effects (1.7-4.0 mmHg). The mechanism likely involves more than direct ACE inhibition, including gut microbiome modulation and antioxidant effects. Deep learning is accelerating the discovery and optimization of dairy-derived bioactive peptides, while waste valorization research is extending the source base beyond traditional milk products.

Frequently Asked Questions

Can dairy peptides lower blood pressure?

Clinical trial evidence shows dairy-derived peptides can produce modest blood pressure reductions, typically 1.7-4.0 mmHg systolic in meta-analyses of lactotripeptide (IPP/VPP) studies. A 2025 RCT with casein peptides GPFPIIV and FFVAPFPEVFGK showed a larger 10.3 mmHg systolic reduction over 12 weeks. Effects are most consistent in mildly hypertensive individuals and may vary by population.

How do milk peptides lower blood pressure?

Dairy peptides primarily inhibit angiotensin-converting enzyme (ACE), the same target as pharmaceutical drugs like lisinopril. Short, proline-rich peptides fit into ACE's active site and block the conversion of angiotensin I to angiotensin II, a vasoconstrictor. Recent evidence suggests additional mechanisms, including gut microbiome modulation and antioxidant protection of blood vessel walls.

What dairy peptides inhibit ACE?

The most studied are VPP (Val-Pro-Pro) and IPP (Ile-Pro-Pro) from casein, which have been tested in over 20 human trials. Longer sequences like GPFPIIV and FFVAPFPEVFGK also show ACE inhibition. Whey proteins yield distinct ACE-inhibitory fragments from alpha-lactalbumin and beta-lactoglobulin. Goat and sheep milk produce additional unique ACE-inhibitory peptides not found in bovine sources.

Are dairy peptides as effective as blood pressure medication?

Dairy peptides are far less potent than pharmaceutical ACE inhibitors. The IC50 values (concentration for 50% inhibition) for dairy peptides are in the micromolar range, compared to nanomolar range for drugs like lisinopril. Clinical blood pressure reductions from dairy peptides (1.7-10 mmHg systolic) are smaller than typical pharmaceutical effects (10-15 mmHg). Dairy peptides are a food-based complement, not a replacement for medication.

Does yogurt or cheese contain blood pressure-lowering peptides?

Fermented dairy products like yogurt, cheese, and kefir contain ACE-inhibitory peptides produced by bacterial proteases during fermentation. A 2025 study showed sheep milk fermented with Lacticaseibacillus paracasei produced peptides with ACE-inhibitory, antidiabetic, and anti-inflammatory activity. The peptide content varies by bacterial strain, fermentation time, and milk source.

Does whey protein lower blood pressure?

Whey protein hydrolysates contain ACE-inhibitory peptides. A 2025 study using deep learning-optimized enzymatic hydrolysis achieved 89% ACE inhibition from whey protein at 1 mg/mL. However, in vitro ACE inhibition does not directly predict blood pressure reduction in humans. Most human trials showing blood pressure effects have used casein-derived peptides (IPP/VPP) rather than whey-derived ones.